Baystreet Staff - Wednesday, October 8, 2025 GT Biopharma Inc 11:21 AM EST - GT Biopharma Inc : Today announced that enrollment in the dose escalation cohorts of the Phase 1 trial, evaluating GTB-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic malignancies, is well on track. GT Biopharma Inc shares N.GTBP are trading off $0.02 at $0.72. Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=GTBP&qmodStoryID=6349480350873598